Rep. Meadows Pursuing Solutions to Rising Prescription Drug Costs

f t # e
WASHINGTON, December 6, 2019 | Ben Williamson (202-225-6401) | comments

Rep. Meadows Pursuing Solutions to Rising Prescription Drug Costs

Washington, D.C. – This week, Rep. Mark Meadows (R-NC) sent a letter to the Federal Trade Commission (FTC) and Food and Drug Administration (FDA) about barriers to market access for low-cost generic prescription medications and possible solutions to rising prescription drug costs.

Under President Trump, the FDA has expedited the approval process for a record-breaking number of generic and biosimilar pharmaceutical products. Unfortunately, many of these lower-cost alternatives have not made it to the market because of anti-competitive barriers to market access. In a letter sent on December 5, 2019, Rep. Meadows expressed his concern over anti-competitive practices, such as patent gaming, that are keeping low-cost prescription drugs off the market, as well as the need for statutory and regulatory resolutions to address this problem. 

The text of Rep. Meadows letter can be found here.

Rep. Meadows released the following statement on the letter:

“Americans continue to bear the burden of rising prescription drug costs, and Congress must make the accessibility of affordable drugs a top priority. Anti-competitive practices are keeping Americans from accessing life-saving medications at affordable prices.  I am ready to take more actions to address the important issue of rising prescription drug prices, and I look forward to partnering with the FDA and FTC to bring about the best outcomes for seniors and patients in Western North Carolina and across the country.”

To read about additional actions Rep. Meadows has taken to address prescription drug costs, click here and here.



f t # e

Stay Connected

Use the form below to sign up for my newsletter and get the latest news and updates directly to your inbox.